Drug Trial News

RSS

The Dream Team opens clinical trial to find better treatment options for pancreatic cancer

A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.

30 Mar 2021

GlyNAC could improve many age-associated defects in older humans

A pilot human clinical trial conducted by researchers at Baylor College of Medicine reveals that supplementation with GlyNAC - a combination of glycine and N-acetylcysteine as precursors of the natural antioxidant glutathione - could improve many age-associated defects in older humans to improve muscle strength and cognition, and promote healthy aging.

29 Mar 2021

Type 2 diabetes drug can successfully reduce symptoms associated with tuberous sclerosis complex

A team of researchers led by UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital (GOSH) has found that metformin - a drug commonly used to treat Type 2 diabetes - can successfully reduce symptoms associated with tuberous sclerosis complex (TSC), including reduction in the frequency of seizures and the size of brain tumors.

29 Mar 2021

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

A new preprint research paper posted to the medRxiv server describes successful immunization of the vaccinated population with a single dose of the Russian-made Sputnik V vaccine.

29 Mar 2021

New ‘SINT1A‘ study explores potential of a probiotic to prevent type 1 diabetes in children

Type 1 diabetes is the most common metabolic disease in children and adolescents worldwide. It can be particularly dangerous as often there is no diagnosis until severe and sometimes life-threatening symptoms have already developed.

26 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

In a paper recently uploaded to the preprint server bioRxiv by Tauzin et al. (March 18th, 2021) the ability of a single dose of mRNA vaccine to induce humoral and T cell responses against mutated variants are demonstrated and found to be reinforced in individuals with a history of COVID-19.

22 Mar 2021

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffering from COVID-19 pneumonia.

22 Mar 2021

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Results from a large clinical trial in the United States and South America indicate that AstraZeneca's COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.

22 Mar 2021

Clofazimine inhibits coronaviruses including SARS-CoV-2, study finds

Researchers at the University of Hong Kong found that Clofazimine, a lipophilic antimicrobial riminophenazine dye used in combination with agents like rifampicin and dapsone to treat leprosy, inhibits coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease.

21 Mar 2021

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

The results of a double-blind, randomized, multisite placebo-controlled trial that was conducted in South Africa show that Oxford’s ChAdOx1 nCoV-19 (AZD1222) vaccine has no efficacy against the B.1.351 variant in preventing mild-to-moderate coronavirus disease 2019 (COVID-19), and shows reduced neutralization properties of developed antibodies. The findings are published in the New England Journal of Medicine.

21 Mar 2021

VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor

Co-founded back in 2014 by VHIO's Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L. has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc (OMO-103).

19 Mar 2021

Anti-SARS-CoV-2 drug candidate enters phase I clinical trial

DC402234 (FB2001), an anti-SARS-CoV-2 drug candidate mainly developed by research team at the Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences enters its Phase I clinical trial in the United States on March 15.

19 Mar 2021

Novel cancer-fighting gene therapy enters phase I clinical trial

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells.

18 Mar 2021

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand.

17 Mar 2021

Evaluation of Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities

The severity of COVID-19 among the residents of long-term care facilities (LTCFs) has been reported to be disproportionately high. Specifically, individuals residing in skilled nursing facilities (SNFs) are found to be the most severely affected, both in terms of morbidity and mortality, and are, thereby, listed for early COVID-19 vaccination. In comparison to the general population, SNF residents are more vulnerable, with a weak immune system.

17 Mar 2021

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

As vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease, roll out in various countries, Moderna ups the game by testing its next-generation COVID-19 vaccine.

16 Mar 2021

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

Researchers in the United States have developed “chimeric” vaccines that provided cross-protection against different strains of sarbecovirus in mice, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

15 Mar 2021

Previous
1
...
61
62
63
64
65
66
67
...
1149
Next

Drug Trial News

The Dream Team opens clinical trial to find better treatment options for pancreatic cancer

GlyNAC could improve many age-associated defects in older humans

Type 2 diabetes drug can successfully reduce symptoms associated with tuberous sclerosis complex

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

New ‘SINT1A‘ study explores potential of a probiotic to prevent type 1 diabetes in children

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Single BNT162b2 mRNA dose induces humoral and T cell responses against mutated variants with a history of COVID-19

RedHill provides opaganib treatment under compassionate use exemption for Swiss COVID-19 patients

AstraZeneca's COVID-19 vaccine protects against symptomatic disease

Clofazimine inhibits coronaviruses including SARS-CoV-2, study finds

ChAdOx1 nCoV-19 offers less protection against South African SARS-CoV-2 variant

VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor

Anti-SARS-CoV-2 drug candidate enters phase I clinical trial

Novel cancer-fighting gene therapy enters phase I clinical trial

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Evaluation of Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities

Testing for mRNA-1283, Moderna's next generation COVID-19 vaccine commences

Chimeric vaccines may provide universal protection against viruses like SARS-CoV-2

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News